Related Experiment Videos
Sirolimus: has it gained from experience with older drugs?
1Analytical Unit, St George's Hospital Medical School, London, UK. d.holt@sghms.ac.uk
Therapie
|August 21, 2002
Summary
Monitoring sirolimus blood concentrations guided early clinical trials and dosing guidelines for this immunosuppressive drug. Analytical validation of these measurements was crucial for its therapeutic use post-kidney transplantation.
Area of Science:
- Pharmacology
- Nephrology
- Clinical Trials
Background:
- Sirolimus is an immunosuppressive drug used after kidney transplantation.
- Therapeutic drug monitoring (TDM) using blood concentrations was standard practice for older immunosuppressants.
- Early development of sirolimus occurred within this context of TDM.
Purpose of the Study:
- To document the role of blood concentration measurements in early sirolimus clinical trials.
- To highlight the validation of analytical methods for sirolimus quantification.
- To examine how concentration-efficacy data informed dosing guidelines.
Main Methods:
- Review of early and pivotal clinical trial data for sirolimus.
- Documentation of analytical method validation for sirolimus assays.
- Analysis of the relationship between sirolimus concentrations and clinical outcomes.
Main Results:
- Blood concentration data were integral to assessing sirolimus efficacy in clinical trials.
- Significant attention was given to validating the analytical techniques used.
- Established practices for older immunosuppressants informed sirolimus TDM.
Conclusions:
- Therapeutic drug monitoring of sirolimus is essential for guiding therapy.
- Concentration-efficacy data significantly influenced the development of dosing guidelines.
- Experience with other immunosuppressants provided a foundation for sirolimus monitoring.